Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage biopharmaceutical pioneer leveraging computational discovery to advance novel cancer immunotherapies. This news hub provides investors and researchers with timely updates on clinical trials, strategic partnerships, and therapeutic innovations emerging from Compugen's AI-driven platform.
Access authoritative updates on key developments including COM701 (anti-PVRIG), COM902 (anti-TIGIT), and collaborative programs with industry leaders. Our curated news collection simplifies tracking of pipeline progress, peer-reviewed research publications, and milestone achievements in immuno-oncology.
Content spans clinical trial results, regulatory milestones, and partner collaboration updates, offering a comprehensive view of Compugen's position in next-generation cancer treatment development. Bookmark this page for streamlined access to verified information about therapeutic candidates and computational discovery breakthroughs.
AstraZeneca (AZN) and Daiichi Sankyo reported initial results from a TROPION-PanTumor03 sub-study showing DATROWAY (datopotamab deruxtecan) plus rilvegostomig produced a confirmed objective response rate (ORR) of 68.2% (95% CI: 45.1–86.1) and disease control rate (DCR) of 95.5% (80% CI: 83.4–99.5) in cisplatin-ineligible first-line metastatic urothelial cancer (n=22).
In the second-line, previously platinum-treated/immunotherapy-naïve cohort (n=18), ORR was 38.9% (95% CI: 17.3–64.3) and median progression-free survival (PFS) was 12.5 months (95% CI: 4.2–NR). Median duration of response was not reached in either cohort. Safety was consistent with known profiles: grade ≥3 treatment-related adverse events occurred in 18.2% (first-line) and 38.9% (second-line); adjudicated ILD events were 1 (4.5%) and 2 (11.1%), respectively.
Compugen (NASDAQ: CGEN) announced a pooled analysis of 60 evaluable patients with platinum resistant ovarian cancer showing COM701 was well tolerated with consistent, durable responses; the abstract was released by ESMO and a poster will be presented on October 18, 2025 in Berlin.
The analysis highlights stronger outcomes particularly in patients without liver metastases and supports testing COM701 as maintenance therapy in earlier, platinum sensitive disease in the ongoing MAIA-ovarian trial. An interim MAIA-ovarian analysis is planned once ~60 participants are evaluable, currently estimated by year-end 2026. Sites are active in the U.S. and Israel, with site activation initiated in France; the company expects cash to fund operations into 2027.
Compugen (Nasdaq: CGEN) will present clinical data from an ongoing first‑in‑human trial of the anti‑IL18BP antibody COM503 (GS‑0321) at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 7–9, 2025 in National Harbor, Maryland.
The poster (Abstract 589) — titled "A First in human clinical trial to assess the anti‑IL18BP antibody, COM503 (GS‑0321) in Participants with Advanced Solid Malignancies" — will be presented by Dr. Manish Sharma on Friday, November 7, 2025. The company described COM503 as part of an ongoing trial in participants with advanced solid malignancies.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, will present research at the Single Cell Genomics 2025 Conference in Stockholm, Sweden from September 15-17, 2025. The presentation will showcase the company's AI/ML-powered computational capabilities in analyzing spatial context of cancer biology.
Dr. Roy Granit, Senior Director and Head of Computational Discovery, will present research titled "Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer" on September 15, 2025, at 2:10 PM CET. The poster presentation (ID: P035) will be available on Compugen's website after the conference.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered computational target discovery, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management will engage in a fireside chat that will be accessible on-demand through Compugen's website starting September 5, 2025, at 7:00 AM ET. The presentation will remain available for 90 days on the company's Investor Relations section.
Compugen (NASDAQ: CGEN) reported Q2 2025 financial results and provided corporate updates. The company dosed its first patient in the MAIA-ovarian platform trial evaluating COM701 as maintenance therapy for platinum-sensitive ovarian cancer. Revenue was $1.3 million, down from $6.7 million in Q2 2024, with a net loss of $7.3 million.
The company maintains a strong financial position with $93.9 million in cash and equivalents, expected to fund operations into 2027. Partner AstraZeneca is advancing rilvegostomig with ten active Phase 3 trials, with upcoming data presentations at ESMO 2025. Additionally, Compugen will present pooled analysis from three Phase 1 trials of COM701 in platinum-resistant ovarian cancer at ESMO 2025.
The company announced leadership changes, with Dr. Eran Ophir taking over as CEO and current CEO Dr. Anat Cohen-Dayag transitioning to Executive Chair in September 2025.Compugen (NASDAQ:CGEN) announced its upcoming presentation at ESMO 2025 in Berlin, Germany. The presentation will feature a pooled analysis of data from three Phase 1 trials evaluating COM701 in platinum resistant ovarian cancer patients.
The analysis includes data from trials testing COM701 as both monotherapy and combination therapy in heavily pretreated patients. Dr. Oladapo Yeku from Massachusetts General Hospital will present the findings on October 18, 2025 at 12:00-12:45 CEST. The poster presentation (#1196P) will subsequently be available on Compugen's website.
Compugen (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company specializing in AI/ML-powered drug target discovery, has scheduled its second quarter 2025 financial results release for Wednesday, August 6, 2025, before U.S. markets open.
The company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Investors can access the call via phone (U.S.: 1-866-744-5399, International: +972-3-918-0644) or through Compugen's website. A replay will be available on the website after the live event.
Compugen (NASDAQ: CGEN) has announced the dosing of the first patient in its global randomized sub-trial 1 of the MAIA-ovarian adaptive platform trial. The study evaluates COM701, a potential first-in-class anti-PVRIG antibody, as maintenance therapy in patients with relapsed platinum-sensitive ovarian cancer.
The trial is supported by strong biological evidence showing high PVRIG pathway expression in ovarian cancer. Previous clinical data demonstrated that COM701, in combination with PD-1 and TIGIT blockade, achieved durable responses in heavily pre-treated platinum-resistant ovarian cancer patients. An interim analysis is planned for the second half of 2026, with researchers considering a three-month improvement in progression-free survival over the six-month benchmark to be clinically meaningful.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
